Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Rasmuson, Agnes ^a   Segerström, Lova ^a   Nethander, Maria ^c   Finnman, Jennie ^b   Elfman, Lotta H M ^a   Javanmardi, Niloufar ^b   Nilsson, Staffan ^d   Johnsen, John Inge ^a   Martinsson, Tommy ^b   Kogner, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; TYROSINE 3 MONOOXYGENASE;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CHROMOSOME 17; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA SEQUENCE; EVENT FREE SURVIVAL; GENETIC DISORDER; HEMIZYGOTE; HOMOZYGOTE; MOUSE; MYCN GENE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; TRANSGENE; TUMOR GROWTH;

ANIMALS; BREEDING; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; FEMALE; HEMIZYGOTE; HOMOZYGOTE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; SEQUENCE ANALYSIS, DNA; TRANSGENES;

MUS;

EID: 84871305046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051297     Document Type: Article

References (22)

1. Brodeur GM, (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
2. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, et al. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM, (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
4. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, et al. (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
5. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, et al. (2010) High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A 107: 4323-4328.
6. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM, (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. Embo J 16: 2985-2995.
7. Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, et al. (2004) Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 101: 12664-12669.
8. Chesler L, Weiss WA, (2011) Genetically engineered murine models-contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol 21: 245-255.
9. Norris MD, Burkhart CA, Marshall GM, Weiss WA, Haber M, (2000) Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 35: 585-589.
10. Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, et al. (2007) Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67: 9435-9442.
11. Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, et al. (2011) Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One 6: e19133.
12. Balamuth NJ, Wood A, Wang Q, Jagannathan J, Mayes P, et al. (2010) Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res 70: 2749-2758.
13. Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, et al. (2003) Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 63: 5266-5273.
14. Haraguchi S, Nakagawara A, (2009) A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse. PLoS One 4: e6902.
15. Weiss WA, Godfrey T, Francisco C, Bishop JM, (2000) Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 60: 2483-2487.
16. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, et al. (2008) High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9: 353.
17. Ramsay G, Stanton L, Schwab M, Bishop JM, (1986) Human proto-oncogene N-myc encodes nuclear proteins that bind DNA. Mol Cell Biol 6: 4450-4457.
18. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, et al. (2008) ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68: 9735-9745.
19. Johnsen JI, Kogner P, Albihn A, Henriksson MA, (2009) Embryonal neural tumours and cell death. Apoptosis 14: 424-438.
20. Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, et al. (2005) Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res 11: 2680-2685.
21. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, et al. (2006) Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146.
22. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, et al. (2008) Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10: 1268-1274.